| HOME >> BIOLOGY >> TECHNOLOGY |
BETHLEHEM, Pa., Jan. 4, 2012 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Edward L. Erickson, president and CEO of Saladax, will be presenting at the Biotech Showcase™ 2012 Conference being held in San Francisco, CA. The presentation will be given on Wednesday, January 11, 2012 at 3:45 p.m. PST on the fourth floor of the Parc 55 Wyndham San Francisco Union Square hotel. Mr. Erickson will provide an overview of the company's business, including its products, sales and marketing activities, strategic alliances and finances.
About My5-FU™
Saladax's first commercially available test for innovative dose management, My5-FU, measures levels of 5-flourouracil (5-FU), a widely prescribed chemotherapy drug used in conjunction with other drugs in first-line therapy for colorectal cancer and other solid tumors. The assay technology enables oncologists to determine the optimal dose of 5-FU for each individual patient, thereby increasing the effectiveness of the drug and lessening the risk of severe toxicity and other side effects.
About Saladax Biomedical, Inc.
Saladax Biomedical develops and commercializes novel diagnostic assays to achieve the promise of personalized medicine through dose management and companion diagnostic products for existing and new therapeutics. The Company's dose management technology enables physicians to optimize drug dosing to meet individual patient needs, leading to improved response and quality of life. The Company's 15 MyCare™ dose management assays are comprised of proprietary, automated and cost-effective in vitro diagnostic tests, with a principal focus in oncology. The first MyCare assay available is for one of the most common anticancer drugs, 5-fluorouracil (5
'/>"/>
| SOURCE Saladax Biomedical, Inc. Copyright©2010 PR Newswire. All rights reserved |